Boundless Bio Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the quarterly period ended March 31, 2026OR For the transition period from _______________ to ____________Commission File Number: 001-41989 BOUNDLESS BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware(State or other jurisdiction ofincorporation or organization)10955 Alexandria Way, Suite 100,San Diego, CA(Address of principal executive offices)Registrant’s telephone number, including area code: (858) 766-9912Former name, former address and former fiscal year, if changed since last report: N/A Title of each class Common stock, par value $0.0001 per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and Large accelerated filerNon-accelerated filerEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 5, 2026, the registrant had 22,464,111 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited) Condensed Balance Sheets Condensed Statements of Operations and Comprehensive LossCondensed Statements of Stockholders’ EquityCondensed Statements of Cash FlowsNotes to Condensed Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND MARKET AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of theSecurities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (theExchange Act). All statements other than statements of historical facts contained in this Quarterly Report are forward-lookingstatements, including statements regarding our future results of operations and financial position, our business strategy, researchand development plans, the anticipated timing, costs, design, and conduct of our ongoing and planned clinical trials and preclinicalstudies for our extrachromosomal DNA (ecDNA) directed therapeutic candidate (ecDTx), our use of the net proceeds from theinitial public offering (IPO) of our common stock, the period over which we estimate our cash position will be sufficient to fundour operations, the sufficiency of our cash position to fund achievement of milestones, including initial clinical data readout, theexpected benefits of the portfolio prioritizations we recently implemented, the timing and likelihood of success, plans, and In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “contemplate,”“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “would,” “target,”or “will” or the negative of these terms or other similar expressions. Our forward-looking statements are only predictions. We havebased our forward-looking statements largely on our current expectations and projections about future events and financial andother trends that we believe may affect our business, financial condition, and results of operations based upon information available •We have a limited operating history, have incurred significant operating losses since our inception and expect to incursignificant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieveprofitability, we may not be able to sustain it; •We will